To the Editor: Dr. Cannistra stated in his review article on cancer of the ovary (Nov. 18 issue)1 that “the regimen of cisplatin plus cyclophosphamide is just as effective as more complicated and toxic regimens, such as those containing altretamine or doxorubicin hydrochloride.” It appears that the author did not review the literature critically. For example, Hainsworth et al. (Cannistra's reference 42) reported a response rate of 96 percent for the combination of altretamine (hexamethylmelamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP)2. More important, the median survival for the entire group of patients was 45 months, and it was 72 months.
ASJC Scopus subject areas